

Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways

Changcun Guo^{a,b,c,1}, Chun-Chi Chang^{a,b,c,1}, Matthew Wortham^{a,b,c}, Lee H. Chen^{a,b,c}, Dawn N. Kernagis^c, Xiaoxia Qin^d, Young-Wook Cho^{e,2}, Jen-Tsan Chi^d, Gerald A. Grant^{a,b,f}, Roger E. McLendon^{a,b,c}, Hai Yan^{a,b,c}, Kai Ge^e, Nickolas Papadopoulos^g, Darell D. Bigner^{a,b,c}, and Yiping He^{a,b,c,3}

^aThe Preston Robert Tisch Brain Tumor Center at Duke, ^bPediatric Brain Tumor Foundation Institute, ^cDepartment of Pathology, ^dInstitute for Genome Sciences and Policy, and ^eDepartment of Surgery, Duke University, Durham, NC 27710; ^fLaboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; and ^gLudwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231

Edited* by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved September 14, 2012 (received for review June 1, 2012)

Myeloid/lymphoid or mixed-lineage leukemia (MLL)-family genes encode histone lysine methyltransferases that play important roles in epigenetic regulation of gene transcription. MLL genes are frequently mutated in human cancers. Unlike MLL1, MLL2 (also known as ALR/MLL4) and its homolog MLL3 are not well-understood. Specifically, little is known regarding the extent of global MLL2 involvement in the regulation of gene expression and the mechanism underlying its alterations in driving tumorigenesis. Here we profile the global loci targeted by MLL2. A combinatorial analysis of the MLL2 binding profile and gene expression in MLL2 wild-type versus MLL2-null isogenic cell lines identified direct transcriptional target genes and revealed the connection of MLL2 to multiple cellular signaling pathways, including the p53 pathway, cAMP-mediated signaling, and cholestasis signaling. In particular, we demonstrate that MLL2 participates in retinoic acid receptor signaling by promoting retinoic acid-responsive gene transcription. Our results present a genome-wide integrative analysis of the MLL2 target loci and suggest potential mechanisms underlying tumorigenesis driven by MLL2 alterations.

tumor suppressor | somatic targeting | S100A gene cluster

Modulation of chromatin accessibility through chromatin remodeling and histone modification is a critical step in regulating eukaryotic gene transcription. Histone H3 lysine 4 (H3K4) methylation by histone methyltransferases is an evolutionarily conserved epigenetic mark for active gene transcription (1). In mammalian cells, six complexes with H3K4 methyltransferase activity have been identified, each with one SET domain-containing methyltransferase subunit, including Set1A, Set1B, and four MLL-family proteins. In humans, these MLL-family genes include *MLL1*, *MLL2* (GenBank accession no. NM_003482; also known as *ALR/MLL4*), *MLL3*, and *MLL4* (GenBank accession no. NM_014727; also known as *MLL2* or *Wbp7*, conflicting with the official symbol for *MLL2*). Each of these proteins is associated with a complex that modulates histone methylation (2). Among the MLL genes, *MLL1* and its homolog *MLL4* have been the most extensively studied, as the former is frequently involved in genetic alterations in leukemia (reviewed in ref. 3). In addition, *MLL4* has been found to be overexpressed in breast and colorectal cell lines (4). *MLL1* and *MLL4* play essential roles in regulating the expression of genes that are involved in cell differentiation and early embryonic development, among which the most notable and best-established are the *Homeobox (Hox)* genes (5, 6).

MLL2 was originally cloned as a human homolog of *Drosophila trithorax* (7). *MLL2* and its homolog, *MLL3*, function distinctly from *MLL1* and *MLL4*. Each of them associates with nuclear receptor coactivator 6 (also known as activating signaling cointegrator 2) to form a complex that contains other subunits including ASH2L, RbBP5, WDR5, DPY30, PTIP, PA1, and UTX (8–10). Together with the chromatin-remodeling complex

SWI/SNF, the MLL2 or MLL3 (hereafter referred to as MLL2/3) complex has been found to play essential roles as a coactivator for transcriptional activation by nuclear hormone receptors (11). Consistent with this notion, previous studies have shown that MLL2/3 complexes regulate *Hox* gene transcription in an estrogen receptor-dependent manner, and that they play critical roles in PPAR γ -dependent adipogenesis (12–14).

Somatically acquired epigenetic changes are prevalent in human cancers. Recent cancer genetics studies have uncovered frequent somatic loss-of-function mutations in the genes encoding MLL2/3 complex subunits in a variety of cancer types. *UTX* was found to be mutated in numerous human cancer types (15–17). *MLL3* was found to be mutated in a subset of colorectal cancers and in transitional cell carcinoma (16, 18–20). Most notably, several recent studies identified frequent *MLL2*-inactivating mutations in non-Hodgkin B-cell lymphomas (21–23). Finally, genes encoding MLL2/3 complex subunits, particularly *MLL2*, *MLL3*, and *UTX*, were found to be mutated in medulloblastoma, establishing them as critical tumor suppressors (24–26).

In contrast to the compelling genetic evidence, much less is known regarding the mechanism underlying the tumor suppressor roles of the MLL2/3 complex. It was shown that knockdown of *MLL2* resulted in reduced cancer cell growth and altered adhesion in HeLa cells (9). An *MLL3*-knockout mouse model study showed that *MLL3* plays a role in DNA damage response in a p53-dependent manner, suggesting that the complex serves as a transcriptional coactivator for p53 (27). The link to p53 is consistent with the tumor suppressor role of the MLL3 complex. However, it is most likely that MLL2/3 epigenetic complexes have a broader role biochemically and that the deficiency of the pathway has a more profound impact on cellular processes. To further elucidate the tumor suppressor role of *MLL2*, we performed a direct profiling of the global loci that are targeted by *MLL2*. Moreover, we show that somatic knockout of *MLL2* in human cells affects the expression of a variety of genes. We note a set of genes that are retinoic acid-responsive and may be directly regulated by *MLL2*. Finally, integrative pathway analysis uncovered various signaling pathways that are regulated by the MLL2 complex. Our results reveal the global and pathway-

Author contributions: C.G. and Y.H. designed research; C.G., C.-C.C., and Y.H. performed research; C.-C.C., Y.-W.C., G.A.G., K.G., N.P., and D.D.B. contributed new reagents/analytic tools; C.G., C.-C.C., M.W., L.H.C., D.N.K., X.Q., J.-T.C., R.E.M., H.Y., N.P., and Y.H. analyzed data; and C.G. and Y.H. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

¹C.G. and C.-C.C. contributed equally to this work.

²Present address: Korea Basic Science Institute Chuncheon Center, Chuncheon-si 200-701, Republic of Korea.

³To whom correspondence should be addressed. E-mail: yiping.he@duke.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1208807109/-DCSupplemental.

specific roles of MLL2 and suggest that it participates in regulating a wide range of pathways with relevance to its role in oncogenesis.

Results

Generation of Endogenous Flag-Tagged MLL2-Expressing Cells. Identifying genomic binding sites is a powerful strategy to reveal genes regulated by transcriptional regulators (5, 28, 29). However, two hurdles confront the direct global profiling of MLL2-targeted loci: (i) It is a massive protein of 5,537 amino acids (~600 kDa), which complicates biochemical studies that require ectopic expression; and (ii) neither a proven-quality antibody nor a human cell assay is available for chromatin immunoprecipitation-sequencing (ChIP-seq). To overcome these obstacles, we have adopted a somatic knockin-based approach in which an endogenous protein is fused with a short tagging peptide, which facilitates antibody-based ChIP studies (30, 31). We chose the HCT116 carcinoma cell line for our study, as it is a near-diploid cell line with well-defined key cancerous pathways. Furthermore, this cell line has homozygous *MLL3*-inactivating mutations, thus preventing compensatory effects from obscuring functional analysis (19). An rAAV-based somatic knockin construct (30, 32, 33) enabled the insertion of a DNA fragment encoding Flag tags immediately upstream of the stop codon of the *MLL2* gene (Fig. 1A and Fig. S1A). In the parental cells, only the nontagged *MLL2* transcript could be detected, whereas in the heterozygous recombinant clones (*MLL2*-Flag), both the nontagged and Flag-tagged transcripts could be detected (Fig. S1B). Anti-Flag immunoblot detected full-length MLL2-Flag proteins in the nuclear extract (Fig. 1B and Fig. S1C). In addition, the endogenous MLL2-Flag protein was suitable for ChIP, as evidenced by the Flag signal in the ChIP fraction from the somatic knockin clones (Fig. S1D). Collectively and consistent with previous studies using the same strategy for ChIP studies

(30), we have established a human cell assay that consists of isogenic cell lines that differ only in the presence or absence of an *MLL2*-Flag allele, thus permitting the direct profiling of MLL2-targeted loci by a proven-quality antibody-based ChIP-seq.

Global Identification of MLL2-Targeted Loci. The parental cell line and MLL2-Flag-expressing cells (clone MLL2-Flag1 and 2) were subjected to anti-Flag antibody-based ChIP-seq procedures (Fig. S2A). We modified a previously described differential tag-density analysis (34, 35) to obtain a global view of MLL2-bound loci. We generated bins (regions) across the human genome and compared the tag density for each bin between the parental and MLL2-Flag-expressing cell lines. The relative tag density of the MLL2-Flag-expressing cell line to the parental line showed frequent spikes (Fig. 1C), indicating an MLL2-Flag-specific enrichment. In contrast, such enrichment was absent in the parental line, as indicated by the reverse tag-density ratio (Fig. 1C). The same set of MLL2-Flag-specific enrichments was also apparent in MLL2-Flag-expressing cell line 2 (Fig. S2B).

To identify MLL2-targeted regions, we applied a criterion by which at least fivefold enrichment was required to identify differential tag density (35). A total of 2,060 MLL2 binding events were identified. The enrichment was validated by independent quantitative PCR (qPCR) of the originally sequenced libraries and independent ChIP-qPCR experiments (Fig. 1D and Fig. S2C and D). Analysis of the global distribution of the binding loci showed that about 59% of them were intragenic (Fig. S3A). The remaining 41% of them were located outside the defined boundary, or intergenic region (Fig. S3A), demonstrating a concentration in intragenic regions of the genome ($P < 0.0001$). Among those intragenic loci, about 15% were within a distal promoter region, whereas most were within a transcript boundary (Fig. S3B). These results are in agreement with previous studies




Fig. 1. Genome-wide profiling of MLL2 binding sites. (A) rAAV vector and somatic targeting of Flag epitope to the carboxyl terminus of MLL2 protein. (B) Immunoblot detection of the endogenous MLL2-Flag protein. (C) ChIP enrichment analysis identified Flag-tagged MLL2-enriched loci across the genome specifically in MLL2-Flag-expressing cells. (Left) For each qualified locus, the ratio of the normalized distinct tag number in the MLL2-Flag-expressing cells to the distinct tag number in the parental cells is plotted. (Right) For each qualified locus, the reverse ratio of normalized distinct tag number (parental to MLL2-Flag 1) is plotted. (D) ChIP coupled with qPCR to confirm the locus identified by ChIP-seq. Results are from three independent ChIP experiments. Error bar stands for standard deviation from three independent ChIP assays. (E) An MLL2-Flag-enriched locus. The distinct coverage of each base in a 6-kb region is plotted. The gene that is most closely associated with the enriched locus and the corresponding transcription factor binding site identified by ENCODE are indicated.

showing the broad distribution of MLL1 across the genome, including many localized within the gene boundary (36).

We then focused on those binding events that surrounded presumed transcript start sites, as they were most likely linked to direct transcriptional regulation (Dataset S1). Close examination of these loci found that all were previously identified as transcription factor binding sites by the ENCODE Project (28), further supporting that they could be directly targeted by transcription regulators (examples in Fig. 1E, Fig. S2D, and Dataset S1). Genes linked to the MLL2-associated loci encode products of diverse functions, including those of signaling transducers, cellular structure proteins, and microRNAs (Dataset S1). It should be noted that the ChIP assay was performed when cells were under standard culture conditions. It is likely that the extent of the MLL2 complex's binding to any locus and its specific function are exogenous signaling- and/or cellular context-dependent and thus will be underestimated by a single study. In this regard, the global map of MLL2 binding sites provides valuable information and opportunities for further studies of this essential epigenetic regulator.

Generation of MLL2-Knockout Colorectal Cancer Cells. To further investigate the function of MLL2, we generated MLL2-null HCT116 cell lines by modifying the somatic recombination such that a fragment of DNA was inserted into the MLL2 gene, effectively generating inactivating mutations similar to those that are frequently found in cancers (Fig. 2A). As expected, cell lines with insertions in both MLL2 alleles ($MLL2^{-/-}$) had complete loss of the wild-type MLL2 genes and transcript, and had no detectable MLL2 protein due to the nonsense mutation and/or altered splicing (Fig. 2B and Fig. S1 E and F).

Gene Expression Analysis of Parental and MLL2-Knockout Cells. To identify downstream events that were regulated by the MLL2 complex, we used microarrays to analyze gene expression in the parental HCT116 cells and $MLL2^{-/-}$ clones. This analysis




Fig. 2. Expression profiling of parental and MLL2-knockout cells. (A) Somatic MLL2 knockout by insertion. A DNA fragment containing a stop codon and a neomycin (neo) selection marker was inserted at the position right before the SET domain-coding sequence. The insertion disrupts MLL2 with or without the presence of the neo selection marker. (B) Anti-MLL2 immunoblot confirms the absence of the expected full-length MLL2 protein in $MLL2^{-/-}$ cells. (C) Unsupervised hierarchical clustering for probes with average linkage was performed to reveal differential expression genes in $MLL2^{-/-}$ clones (1–4) in comparison with parental cells. Triplicates for each clone were included and compared with the average expression value of parental cells. Red denotes relative overexpression, and green denotes relative reduced expression level. The exact levels of change for these probes are shown in Dataset S2.

revealed that a subset of genes that were associated with MLL2-enriched loci displayed reduced expression in $MLL2^{-/-}$ cell lines (Dataset S2). The decreased expression was accompanied by reduced H3K4 trimethylation (Fig. S4). Compared with the overall frequency of genes that were down-regulated by MLL2 deficiency, the ChIP-identified subset of genes was significantly enriched for those whose expression was attenuated in the $MLL2^{-/-}$ cell lines [5.54% (24/433) versus 1.10% (228/20,722) overall when the same cutoff was applied; $P < 0.0001$]. Gene expression changes were further verified by qPCR of transcripts from the original $MLL2^{-/-}$ clones and by microarray analysis in an additional pair of $MLL2^{-/-}$ lines (Fig. 2C and Dataset S2). Interestingly, there were also genes that displayed higher expression levels in $MLL2^{-/-}$ cells than in the parental cells (Fig. 2C and Dataset S2), consistent with an indirect effect. Overall, most of the down-regulation of gene expression was moderate, in agreement with the observation that deletion of a single MLL-family gene has only minimal effects on global H3K4 methylation (37, 38). The moderate expression changes might also reflect the relatively low expression level of some genes in the parental cells without an exogenous stimulus, suggesting that MLL2 can be poised at various loci independent of transcriptional activation. Nevertheless, these results identified a subset of genes as candidate targets regulated by MLL2 in the specified cellular context.

MLL2 Binds S100A-Family Genes and Regulates Their Expression. Further examination of the expression profile revealed genes that were potentially direct targets of MLL2 (Dataset S2). Unlike MLL1, MLL2 was not associated with the Hox-family gene cluster in the present study, probably due to the difference in gene functions and/or distinct cellular contexts (5). Instead, we noticed that MLL2 was associated with and likely directly regulated another family gene cluster, the S100 alpha (S100A) genes (Fig. 3A and B and Fig. S5). Among the 16 S100A genes, a phylogenetically related subgroup of five (S100A6, 5, 4, 3, and 2) cluster within an ~30-kb region in chromosome 1q21, a region that is frequently altered in cancers (39, 40). MLL2 binding loci were found to localize around the transcriptional start sites of S100A2–6, and at ~40 kb upstream of this cluster, where S100I6, 14, 13, and 1 are located (Fig. 3A). Microarray analysis revealed the apparent down-regulation of the S100A2, 3, 4, 5, 14, and 16 genes and a slight reduction of the S100A6 gene (Fig. 3C). Independent microarray analysis and qPCR confirmed the down-regulation of these genes in another pair of $MLL2^{-/-}$ cell lines derived from a different progenitor $MLL2^{+/+}$ line (Fig. S6).

MLL2 Regulates Gene Expression of Multiple Signaling Pathways. Because coactivators such as MLL2 function together with other transcription factors in regulating gene transcription, we investigated which transcription factors were associated with the MLL2 pathway. Genes that were found to be associated with MLL2-bound loci (Dataset S1; among them, 476 were annotated with official gene symbols) were subjected to Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) for the identification of transcription factors potentially cooperating with MLL2. Interestingly, among the enriched transcription factors were NR3C1, a nuclear receptor, and p53 (Dataset S3). In support of this finding, we also found that many MLL2 binding sites overlapped with previously identified p53-targeted regions (Dataset S1) (29). Although this analysis did not point to a direct interaction between MLL2 and the identified transcription factors, these findings provided promising candidate pathways for further studies. To further gain an integrative view of the functional consequence of MLL2 in the context of cellular signaling pathways, we selected the genes whose expression was down-regulated by MLL2 loss of function and subjected them to IPA canonical pathway analysis (Dataset S2). Analysis of pathways that may be regulated by MLL2 revealed the potential effects of




Fig. 3. MLL2 binding to the *S100A* gene cluster. (A) Schematics of the *S100A* gene cluster region on chromosome 1q21.3. MLL2 bindings within this region (as identified in the present study) are marked (red rectangles). Among these binding events, the *S100A2* site was the best-enriched and identified in the original ChIP-seq. The other binding sites have less than fivefold enrichment in the ChIP-seq analysis but were confirmed by an independent ChIP-qPCR. (B) The MLL2 binding site near the transcript start of the *S100A2* gene is depicted at single-base-pair resolution based on the normalized distinct tag coverage from the ChIP-seq experiment. (C) Microarray profiling shows reduced expression of the clustered *S100A* genes in *MLL2*^{-/-} cells, in comparison with parental cells.

MLL2 on a broad range of cellular processes. Among those signaling pathways that were found to be significantly related were cAMP-mediated signaling (Table 1). Most intriguingly, this canonical pathway and the p53 pathway are among the unique signature pathways that define a particular subtype of medulloblastoma (41).

MLL2 Regulates the Expression of the Retinoic Acid-Responsive Gene *ASB2*. We next sought to validate the functional role of MLL2 in regulating the transcription of the genes we identified. The pathway analysis revealed that one of the interesting categories of genes was those that respond to nuclear hormones. Interestingly, one of the pathways overrepresented in both MLL2-bound and MLL2-responsive gene sets was retinoic acid signaling. A more careful examination of MLL2-enriched loci revealed that many of them indeed overlapped with retinoic X receptor α ChIP-seq loci (28) (Dataset S1). One of the genes that was linked to the MLL2-enriched loci was *ASB2* (Fig. 1E), whose expression was previously found to be induced by retinoic acid in leukemia cells (42, 43). This gene was expressed at a relatively low level in parental HCT116 cells, and quantitative analysis of the *ASB2* transcript showed that its expression was further reduced in the *MLL2*^{-/-} cell lines (Fig. 4A). To verify the role of the MLL2 complex in mediating the retinoic acid response, we tested whether HCT116 cells responded to retinoic acid transcriptionally using

ASB2 as a marker gene. Treatment of parental HCT116 cells with retinoic acid induced robust *ASB2* expression (Fig. 4B). Furthermore, whereas retinoic acid treatment also led to an increased *ASB2* transcript level over a very low basal level in the *MLL2*^{-/-} cells, the expression level of *ASB2* was significantly lower than the level seen in the *MLL2*-intact parental cells upon retinoic acid treatment (Fig. 4B), indicating that MLL2 involvement accounted for the majority of increased *ASB2* expression in response to retinoic acid. Collectively, these results validated the roles of MLL2 uncovered by ChIP-seq and gene expression studies, and suggest an extensive involvement of MLL2 in a variety of cellular signaling pathways.

Discussion

In this study, we profiled the global binding loci of the MLL2 complex to reveal the scope of its gene regulation. In a parallel effort, we generated *MLL2*-null cell lines for the identification of genes whose expression was affected by MLL2 loss of function. A combinatorial analysis of these results provided a list of genes that are regulated by the MLL2 complex. These genes encode proteins of distinct functions, which support the notion that MLL2 plays roles in multiple signaling pathways and cellular processes. Among those that are direct targets of the MLL2 complex are the *S100A*-family genes. The *S100A*-family genes encode proteins containing EF-hand calcium-binding motifs that

Table 1. Ingenuity Pathway Analysis of genes down-regulated by MLL2 loss of function

Pathway	P value	Gene list
cAMP-mediated signaling	0.0023	PDE12, PKIA, PKIB, RPS6KA1, PPP3CA
LPS/IL-1-mediated inhibition of RXR function	0.0024	FABP6, ABCC2, ABCC3, ACOX2, IL-18
Hepatic cholestasis	0.0032	ABCC2, ABCC3, FABP6, IL-18
FXR/RAR activation	0.0062	ABCC2, FABP6, IL-18
B-cell development	0.01	IL7, IL7R
Cardiac β -adrenergic signaling	0.0199	PDE12, PKIA, PKIB
Role of JAK1 and JAK3 in Yc cytokine signaling	0.0299	IL7, IL7R
PXR/RXR activation	0.0354	ABCC2, ABCC3
WNT/ β -catenin signaling	0.0368	GJA1, SOX4, SOX9
Embryonic stem cell differentiation into cardiac lineages	0.0427	ISL1
HER-2 signaling in breast cancer	0.0433	ITGB4, NRG1

cAMP, cyclic adenosine monophosphate; FXR, farnesoid X receptor; LPS, lipopolysaccharide; RXR, retinoid X receptor; PXR, pregnane X receptor; RAR, retinoic acid receptor.




Fig. 4. MLL2 regulates the expression of retinoic acid target genes. (A) Reduced expression of *ASB2* (a retinoic acid response gene) in *MLL2*^{-/-} cells, as determined by RT-qPCR. (B) Attenuated *ASB2* gene expression in response to retinoic acid treatment in *MLL2*^{-/-} cells. Four *MLL2*^{-/-} lines derived from two different *MLL2*^{+/-} progenitor lines were treated with DMSO or with 1 μ M retinoic acid for 48 h. Quantitative RT-PCR was performed to determine the relative expression level of *ASB2* genes. Error bars stand for standard deviation from three independent experiments.

regulate intracellular calcium signaling and participate in a number of cellular processes (44). In particular, *S100A2* was identified as a putative tumor suppressor (45, 46), possibly through regulating the p53 pathway (47). The regulation of the *S100A* gene cluster by the MLL2 complex reveals an additional gene cluster that is transcriptionally coregulated by an MLL-family epigenetic regulator, reminiscent of the *Hox* gene cluster's regulation by MLL1 (5).

Our findings provide evidence to expand previously established links between H3K4 methyltransferases and other pathways, and suggest that the roles of MLL2 may be extensive. p53 and nuclear hormone receptors are among those in the top of the list in the transcription factor and pathway analysis from our unbiased binding site and gene expression profiling for MLL2. The link of MLL2 to the p53 pathway is in good agreement with the previous MLL3-p53 findings (27), and supports the role of the MLL2 complex as a tumor suppressor in a variety of cancer types. Another example of interest was the potential role of the MLL2 complex in cholestasis signaling, as previously the MLL3 complex was found to play a role in adipogenesis and cholestasis (13, 48). This is supported by the discovery that HNF4A, a nuclear receptor involved in hepatic lipid metabolism and pancreatic islet function (49, 50), is among the transcription factors linked to the MLL2 complex. Finally, among the most interesting discoveries are the signaling pathways that were not previously known to be associated with MLL2 or MLL3 complexes, such as cAMP signaling. These findings, and those from previous work, provide insight that may inform the future search for mechanisms underlying the role of MLL2 in pathogenesis: (i) It is possible that one or more of these currently described pathways contributes to MLL2 mutation-driven tumorigenesis in a cell type-specific manner, whereas the p53 pathway acts independently of cancer type; (ii) comparing gene expression profiles (*MLL2* wild-type versus mutant) in different cellular contexts may suggest the primacy of these pathways in tumors bearing MLL2 pathway alterations; and (iii) gene expression signatures characteristic of *MLL2* mutations may be exploited for tumor classification, a possibility raised by the findings that several MLL2-affected pathways overlap with the pathways that distinguish particular subgroups of medulloblastoma (41), a cancer that has frequent *MLL2* mutations (24–26).

Our profiling study uncovered global distribution characteristics of MLL2 that mirror those of MLL1. Studies of MLL1 have shed light on its global effect on gene expression, including the broad genomic distribution and its specific roles in *Hox* gene transcription (5). These results have illuminated mechanisms underlying the role of MLL1 in normal hematopoiesis and in

leukemogenesis. Previous studies of MLL2 and MLL3 identified roles in nuclear hormone signaling, particularly estrogen receptor signaling, and revealed their similarity to MLL1 in regulating inducible gene expression (5, 12, 51). Further studies will be necessary to test the association of the genes/pathways described herein with MLL-family members. It is important to point out that although the MLL2 binding events we identified were highly specific, we could not rule out binding of loci that were not positively identified. Just like any antibodies used in similar studies, nonspecific antibody binding would have prevented real binding events from being discovered if they colocalize with the former. Secondly, the cellular context limitation was also notable, because certain MLL2 binding events may be detectable only upon specific exogenous signals or only in certain types of cells.

In summary, the present study advances our understanding of MLL2 in the following ways: (i) It revealed the global binding profile of the MLL2 protein and the broad extent and characterization of MLL2 distribution across the genome, and thus provides insight into the potential roles of this important epigenetic regulator; (ii) it identified various downstream pathways that are regulated by MLL2, establishing a basis for studying the mechanism underlying the role of MLL2 in development and disease; (iii) it uncovered the regulatory role of MLL2 in the transcription of clustered *S100A*-family genes that encode for a group of broadly distributed yet understudied proteins; (iv) it further established the extensive role of MLL2 in nuclear hormone signaling and provided a rationale for future studies on the link between nuclear hormone signaling and diseases associated with *MLL2* alterations; and finally, (v) our work further validated the somatic recombination-based approach for studying massive proteins, such as MLL2, for which overexpression is a challenging task. The findings and approaches undertaken here have laid the foundation for further understanding the function of MLL2 and have implications for future research on the rapidly accumulating list of epigenetic regulator genes that have been found to be altered in cancers and other diseases.

Materials and Methods

Somatic Targeting. The vector and protocol for epitope tag targeting and gene knockout have been described previously (28, 49, 50). Briefly, homology arms surrounding the DNA insertion site were amplified by and cloned into an rAAV vector. Following rAAV infection, cells were screened for recombinant clones. Positive clones were infected with an adenovirus expressing Cre recombinase (Vector Biolabs) to remove the drug-resistance cassette. For homozygous gene disruption, the second allele of the *MLL2* gene was then targeted following the same procedure, except that the drug-resistance cassette was not removed. Two independent *MLL2*^{+/-} clones

were used for the second *MLL2* allele knockout to generate four homozygous lines (*MLL2*^{-/-}) for experiments.

Nuclear Extraction, Immunoprecipitation, and Western Blot. Nuclear extraction and IP were performed following a previously described protocol (8). Immunoblot detection of *MLL2* was performed by following the standard Western blot procedure, except that a TE22 tank transfer unit (Hoefer) was used for the protein transfer.

ChIP-Seq and Data Analysis. The ChIP procedure is described in detail in *SI Materials and Methods*. Briefly, cells were cross-linked and cell lysate was then prepared and subjected to sonication to shear the chromatin. Magnetic beads (New England Biolabs) conjugated with anti-Flag antibody (F3165; Sigma) were used for IP. ChIP-derived DNA was recovered for Illumina GAI-compatible library preparation. Libraries were used for sequencing or qPCR analysis. High-throughput sequencing was performed on the Illumina GAI system. Tags were mapped to the human genome

(release hg18) by using the Illumina alignment software Eland. Detailed tag assignment and differential density analysis are described in *SI Materials and Methods*.

Quantitative PCR. SYBR label-based qPCR was performed on a 7900HT fast real-time PCR system (Applied Biosystems) and analyzed with the machine software. For qPCR evaluation of gene expression, reverse transcription was performed to convert total RNA into single-strand cDNA using the SuperScript II system (Invitrogen) before qPCR.

ACKNOWLEDGMENTS. We thank Zhenghe Wang (Case Western Reserve University) for the somatic knockin construct and advice on generating somatic knockin cell lines and the Duke Microarray Core Facility (a Duke National Cancer Institute and Duke Institute for Genome Sciences and Policy shared-resource facility) for technical support, microarray data management, and feedback on the generation of the microarray data reported in this manuscript. This work was supported by the Pediatric Brain Tumor Foundation and The Preston Robert Tisch Brain Tumor Center at Duke (Y.H.) and the Duke Cancer Institute (Y.H.).

1. Ruthenburg AJ, Allis CD, Wysocka J (2007) Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark. *Mol Cell* 25(1):15–30.
2. Dou Y, et al. (2006) Regulation of *MLL1* H3K4 methyltransferase activity by its core components. *Nat Struct Mol Biol* 13(8):713–719.
3. Muntean AG, Hess JL (2012) The pathogenesis of mixed-lineage leukemia. *Annu Rev Pathol* 7:283–301.
4. Natarajan TG, et al. (2010) Epigenetic regulator *MLL2* shows altered expression in cancer cell lines and tumors from human breast and colon. *Cancer Cell Int* 10:13.
5. Guenther MG, et al. (2005) Global and Hox-specific roles for the *MLL1* methyltransferase. *Proc Natl Acad Sci USA* 102(24):8603–8608.
6. Glaser S, et al. (2006) Multiple epigenetic maintenance factors implicated by the loss of *MLL2* in mouse development. *Development* 133(8):1423–1432.
7. Prasad R, et al. (1997) Structure and expression pattern of human *ALR*, a novel gene with strong homology to *ALL-1* involved in acute leukemia and to *Drosophila trithorax*. *Oncogene* 15(5):549–560.
8. Cho YW, et al. (2007) *PTIP* associates with *MLL3*- and *MLL4*-containing histone H3 lysine 4 methyltransferase complex. *J Biol Chem* 282(28):20395–20406.
9. Issaeva I, et al. (2007) Knockdown of *ALR (MLL2)* reveals *ALR* target genes and leads to alterations in cell adhesion and growth. *Mol Cell Biol* 27(5):1889–1903.
10. Goo YH, et al. (2003) Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. *Mol Cell Biol* 23(1):140–149.
11. Lee S, et al. (2009) Crucial roles for interactions between *MLL3/4* and *INI1* in nuclear receptor transactivation. *Mol Endocrinol* 23(5):610–619.
12. Ansari KI, Hussain I, Shrestha B, Kasiri S, Mandal SS (2011) *HOXC6* is transcriptionally regulated via coordination of *MLL* histone methylase and estrogen receptor in an estrogen environment. *J Mol Biol* 411(2):334–349.
13. Lee J, et al. (2008) Targeted inactivation of *MLL3* histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for *MLL3* in adipogenesis. *Proc Natl Acad Sci USA* 105(49):19229–19234.
14. Cho YW, et al. (2009) Histone methylation regulator *PTIP* is required for *PPAR γ* and *C/EBP α* expression and adipogenesis. *Cell Metab* 10(1):27–39.
15. Dalglish GL, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* 463(7279):360–363.
16. Gui Y, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet* 43(9):875–878.
17. van Haafden G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene *UTX* in human cancer. *Nat Genet* 41(5):521–523.
18. Sjöblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. *Science* 314(5797):268–274.
19. Watanabe Y, et al. (2011) Frequent alteration of *MLL3* frameshift mutations in microsatellite deficient colorectal cancer. *PLoS One* 6(8):e23320.
20. Vakoc CR, et al. (2009) Low frequency of *MLL3* mutations in colorectal carcinoma. *Cancer Genet Cytogenet* 189(2):140–141.
21. Morin RD, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* 476(7360):298–303.
22. Pasqualucci L, et al. (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* 43(9):830–837.
23. Lohr JG, et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc Natl Acad Sci USA* 109(10):3879–3884.
24. Parsons DW, et al. (2011) The genetic landscape of the childhood cancer medulloblastoma. *Science* 331(6016):435–439.
25. Pugh TJ, et al. (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature* 488(7409):106–110.
26. Jones DT, et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. *Nature* 488(7409):100–105.
27. Lee J, et al. (2009) A tumor suppressive coactivator complex of p53 containing *ASC-2* and histone H3-lysine-4 methyltransferase *MLL3* or its paralogue *MLL4*. *Proc Natl Acad Sci USA* 106(21):8513–8518.
28. Myers RM, et al.; ENCODE Project Consortium (2011) A user's guide to the Encyclopedia of DNA Elements (ENCODE). *PLoS Biol* 9(4):e1001046.
29. Wei CL, et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. *Cell* 124(1):207–219.
30. Zhang X, et al. (2008) Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. *Nat Methods* 5(2):163–165.
31. Wang Z (2009) Epitope tagging of endogenous proteins for genome-wide chromatin immunoprecipitation analysis. *Methods Mol Biol* 567:87–98.
32. Rago C, Vogelstein B, Bunz F (2007) Genetic knockouts and knockins in human somatic cells. *Nat Protoc* 2(11):2734–2746.
33. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B (2004) Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. *Nucleic Acids Res* 32(1):e3.
34. Robertson G, et al. (2007) Genome-wide profiles of *STAT1* DNA association using chromatin immunoprecipitation and massively parallel sequencing. *Nat Methods* 4(8):651–657.
35. Johnson DS, Mortazavi A, Myers RM, Wold B (2007) Genome-wide mapping of in vivo protein-DNA interactions. *Science* 316(5830):1497–1502.
36. Milne TA, et al. (2005) *MLL* associates specifically with a subset of transcriptionally active target genes. *Proc Natl Acad Sci USA* 102(41):14765–14770.
37. Lubitz S, Glaser S, Schaft J, Stewart AF, Anastassiadis K (2007) Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase *MLL2*. *Mol Biol Cell* 18(6):2356–2366.
38. Wang P, et al. (2009) Global analysis of H3K4 methylation defines *MLL* family member targets and points to a role for *MLL1*-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. *Mol Cell Biol* 29(22):6074–6085.
39. Craig RW, et al. (1994) Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: *MCL1* maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. *Genomics* 23(2):457–463.
40. Engelkamp D, Schäfer BW, Mattei MG, Erne P, Heizmann CW (1993) Six S100 genes are clustered on human chromosome 1q21: Identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E. *Proc Natl Acad Sci USA* 90(14):6547–6551.
41. Northcott PA, et al. (2011) Medulloblastoma comprises four distinct molecular variants. *J Clin Oncol* 29(11):1408–1414.
42. Guibal FC, et al. (2002) *ASB-2* inhibits growth and promotes commitment in myeloid leukemia cells. *J Biol Chem* 277(1):218–224.
43. Kohroki J, et al. (2001) *ATRA*-regulated *Asb-2* gene induced in differentiation of HL-60 leukemia cells. *FEBS Lett* 505(2):223–228.
44. Wolf S, Haase-Kohn C, Pietzsch J (2011) S100A2 in cancerogenesis: A friend or a foe? *Amino Acids* 41(4):849–861.
45. Feng G, Xu X, Youssef EM, Lotan R (2001) Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. *Cancer Res* 61(21):7999–8004.
46. Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R (1992) Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. *Proc Natl Acad Sci USA* 89(6):2504–2508.
47. Mueller A, et al. (2005) The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. *J Biol Chem* 280(32):29186–29193.
48. Ananthanarayanan M, et al. (2011) Histone H3K4 trimethylation by *MLL3* as part of *ASCOM* complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. *Am J Physiol Gastrointest Liver Physiol* 300(5):G771–G781.
49. Odom DT, et al. (2004) Control of pancreas and liver gene expression by HNF transcription factors. *Science* 303(5662):1378–1381.
50. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte nuclear factor 4 α (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol Cell Biol* 21(4):1393–1403.
51. Dreijerink KM, et al. (2006) *Menin* links estrogen receptor activation to histone H3K4 trimethylation. *Cancer Res* 66(9):4929–4935.